Clinical Trials Sponsored by TILT Biotherapeutics Ltd.

Total 74 results

TILT Biotherapeutics Ltd.

Recruiting

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

Melanoma | Head and Neck Squamous Cell Carcinoma

United States, Finland
TILT Biotherapeutics Ltd.

Recruiting

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (TUNIMO)

Solid Tumor

Finland
TILT Biotherapeutics Ltd.

Active, not recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

Metastatic Melanoma

France, Denmark
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Advanced Malignant Tumors

China
Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
NovaRock Biotherapeutics, Ltd

Completed

A Study of NBL-012 in Healthy Chinese Subjects

Healthy Subjects

China
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-028 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
NovaRock Biotherapeutics, Ltd

Not yet recruiting

Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Neovascular Age-Related Macular Degeneration

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Innostellar Biotherapeutics Co.,Ltd

Recruiting

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-Related Macular Degeneration

China
Innostellar Biotherapeutics Co.,Ltd

Active, not recruiting

Safety and Tolerability of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

Inherited Retinal Dystrophy Associated With RPE65 Mutations

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Advanced Solid Tumor

Australia, China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Multiple Myeloma

China
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1)

Multiple Myeloma

China
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Study of EMB-02 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Australia, China, United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Unknown

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Solid Tumor | CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
EpimAb Biotherapeutics (Suzhou)Co., Ltd.

Recruiting

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Advanced/Metastatic Solid Tumors | Relapse/Refractory Lymphoma

China, Australia
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

China, Australia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Nanjing IASO Biotherapeutics Co.,Ltd

Not yet recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

CAR-T for r/r Malignant Tumors in Children

Child, Only | Malignant Tumor | CAR-T

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
Tongji Hospital
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System (CARTinNS)

Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Immune-Mediated Necrotizing Myopathy

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Conjupro Biotherapeutics, Inc.
CSPC-NBP Pharmaceutical Co., Ltd.

Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Breast Cancer | Peripheral Neuropathy
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Follicular Lymphoma | B Cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Plasma Cell Neoplasm | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Primary Cutaneous Follicle Centre Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
Conjupro Biotherapeutics, Inc.
CSPC Megalith Biopharmaceutical Co., Ltd.

Withdrawn

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

Gastric Cancer | Pancreatic Cancer
Conjupro Biotherapeutics, Inc.
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Hypertension

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
Wuhan Union Hospital, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Conjupro Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Withdrawn

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Peripheral T Cell Lymphoma

United States
Chunrui Li
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Extramedullary Multiple Myeloma

China
Conjupro Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Solid Tumor

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sir Run Run Shaw Hospital

Completed

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Soochow University

Recruiting

UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Neoplasms | Neoplasm Metastasis | Metastatic Gastrointestinal Carcinoid Tumor

United States, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | B Acute Lymphoblastic Leukemia

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Multiple Myeloma

China

Clinical Trials Sponsored by TILT Biotherapeutics Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations